WASHINGTON, DC - Members of the Subcommittee on Commerce, Manufacturing, and Trade this week met with job-creators and industry experts to discuss American manufacturing. Hosted by Rep. Brett Guthrie (R-KY), the subcommittee's Jobs and Innovation Forum discussed ways to "Make it Easier to Make it in America." The U.S. is the world's largest manufacturing economy but certain policies and regulations are currently threatening the industry and America's competitiveness.
WASHINGTON, DC - House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Health Subcommittee Chairman Joe Pitts (R-PA) today released the following statements after the White House doubled down on an overreaching mandate that violates employers and individuals' conscience:
WASHINGTON, DC - House Energy and Commerce Committee Chairman Fred Upton joined every Republican member of the Subcommittee on Oversight and Investigations in urging full White House compliance related to the Committee's subpoenas on Solyndra. Despite repeated attempts by the Committee to accommodate the White House, the White House has turned over only 515 pages of internal West Wing Solyndra communications since the subpoenas were issued nearly 100 days ago on November 3, 2011.
WASHINGTON, DC - Environment and Economy Subcommittee Chairman John Shimkus (R-IL) met with reporters recently to outline a 2012 agenda for the subcommittee that focuses on protecting the American people, creating jobs, eliminating government waste. The agenda includes: Protecting our Nuclear Future
WASHINGTON, DC - Rep. Tim Murphy (R-PA), House Energy and Commerce Health Subcommittee Chairman Joe Pitts (R-PA), Ranking Member Henry A. Waxman (D-CA), and Subcommittee Ranking Member Frank Pallone (D-PA) yesterday introduced the Generic Drug and Biosimilar User Fee Act of 2012 (H.R. 3988), which authorizes a generic drug user fee proposal that was recently agreed to by the U.S. Food and Drug Administration and generic drug manufacturers. The user fee provides resources to the FDA to ensure that patients have access to lower cost generic drugs more quickly.